December 26, 2017 / 10:41 AM / 5 months ago

BRIEF-DelMar Pharmaceuticals Announces Fast Track Designation For VAL-083 In Recurrent Glioblastoma

Dec 26 (Reuters) - DelMar Pharmaceuticals Inc:

* DELMAR PHARMACEUTICALS ANNOUNCES FAST TRACK DESIGNATION FOR VAL-083 IN RECURRENT GLIOBLASTOMA

* DELMAR PHARMACEUTICALS INC SAYS FAST TRACK STATUS APPLIES TO TWO ONGOING CLINICAL TRIALS TO EVALUATE VAL-083 AS A POTENTIAL TREATMENT FOR RGBM Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below